Efficacy of Cafon gel on cutaneous infection with herpes simplex virus (HSV-2) and acyclovir-resistant HSV in mice

Journal of Dermatological Science

Volumn 13, Issue 3, 1996, Pages 237-241

  Yoshida, Yoshihiro ^a   Yamamura, Jun Ichi ^a   Sato, Hitoshi ^a   Koyasu, Makiko ^a   Obara, Yoshihiko ^a   Sekiguchi, Hideo ^b   Kawana, Takashi ^c   Shiraki, Kimiyasu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Sato Pharmaceutical Co Ltd   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

acyclovir resistant HSV; caffeine gel; cutaneous HSV infection; herpes simplex virus 2

Indexed keywords

ACICLOVIR; CAFFEINE; CAFON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX VIRUS 2; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN DEFECT; TOPICAL DRUG ADMINISTRATION; VIRUS INFECTION;

EID: 0030484023     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-1811(97)89474-1     Document Type: Article

References (28)

1. [1] Shiraki K, Rapp F: Effects of caffeine on herpes simplex virus. Intervirology 29: 235-240, 1988.
2. [2] Yamamura J, Koyasu M, Sato H, Kurokawa M, Yoshida Y, Amahabu Y, Shiraki K: Topical treatment of cutaneous herpes simplex virus-1 infection in mice with a specially formulated caffeine gel (Cafon). J Dermatol Sci 12: 50-55, 1996.
3. [3] Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer H: Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 74: 5716-5720, 1977.
4. [4] Meyers JD, Wade JC, Mitchell CD, Saral R, Lietman PS, Durack MB, Levin MJ, Segreti AC, Balfour HHJr: Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromized host. Am J Med 73: 229-235, 1982.
5. [5] Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias AJ, Soong S-J, the NIAID Collaborative Antiviral Study Group: vidarabine versus acyclovir therapy in herpes simplex virus encephalitis. N Engl J Med 314: 144-149, 1986.
6. [6] Burns WH, Saral R, Santos GW, Lietman PS, Mvlaren C, Barry DW: Isolation and characterization of resistant herpes simplex virus after acyclovir therapy. Lancet i: 421-423, 1892.
7. [7] Sibrack CD, Gutman LT, Wilfert CM, McLaren C, St Clair MH, Keller PM, Barry DW: Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis 146: 673-682, 1982.
8. [8] Wade JC, McLaren C, Meyers JD: Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis 148: 1077-1082, 1983.
9. [9] Norris SA, Kessler HA, Fife KH: Severe progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis 57: 209-210, 1988.
10. [10] Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, Grant RM, Crumpacker CS: Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 320: 293-296, 1989.
11. [11] Chatis PA, Miller CH, Schrager LE, Crumpacker CS: Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 320: 297-300, 1989.
12. [12] Oliver NM, Collins P, Van der Meer J, Van't Wout JW: Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir. Antimicrob Agents Chemother 33: 635-640, 1989.
13. [13] Safrin S, Assaykeen T, Follansbee S, Mills J: Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: Preliminary data. J Infect Dis 161: 1078-1084, 1990.
14. [14] Birch CJ, Tachedjian G, Doherty RR, Hayes K, Gust ID: Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis 162: 731-734, 1990.
15. [15] Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HHJr: Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intrn Med 112: 416-422, 1990.
16. [16] Safrin S, Crumpacker C, Chatis P, Davis R, Hafner R, Rush J, Kessler HA, Landry B, Mills J, other members of the AIDS clinical trials group: a controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 325: 551-555, 1991.
17. [17] Nugier F, Colin JN, Aymard M, Langlois M: Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol 36: 1-12, 1992.
18. [18] Kumano Y, Yamamoto M, Mori R: Protection against herpes simplex virus infection in mice by recombinant murine interferon-β in combination with antibody. Antiviral Res 7: 289-230, 1987.
19. [19] Kurokawa M, Ochiai H, Nagasaka K, Neki M, Xu H, Kadota S, Sutardjo S, Matsumoto T, Namba T, Shiraki K: Antiviral traditional medicines against herpes simplex virus (HSV-1), polio virus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res 22: 175-188, 1993.
20. [20] Kurokawa M, Nagasaka K, Hirabayashi T, Uyama S, Sato H, Kageyama T, Kadota S, Ohyama H, Hozumi T, Namba T, Shiraki K: Efficacy of traditional medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo. Antiviral Res 27: 19-37, 1995.
21. [21] Dubbs DR, Kit S: Mutant strains of herpes simplex virus deficient in thymidine kinase-inducing activity. Virology 22: 493-502, 1964.
22. [22] Shiraki K, Ochiai H, Okuno T, Ogino S, Hayashi K, Yamanishi K, Takahashi M: Comparison of antiviral assay methods using cell-free and cell-associated varicellazoster virus. Antiviral Res 18: 209-214, 1992.
23. [23] Simmons A, Nash AA: Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease. J Virol 52: 816-821, 1984.
24. [24] Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK: A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med 306: 1313-1319, 1982.
25. [25] Kinghorn GR, Turner EB, Barton IG, Potter CW, Burke CA, Fiddian AP: Efficacy of topical acyclovir cream in first and recurrent episodes of genital herpes. Antiviral Res 3: 291-301, 1983.
26. [26] De Clercq E: Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds. Antimicrob Agents Chemother 26: 155-159, 1984.
27. [27] Sacks SL, Tyrrell LD, Lawee D, Schlech W, 3d Gill MJ, Aoki FY, Martel AY, Singer J: Randomized, double-blinded, placebo-controlled, clinic-initiated, Canadian multicenter trial of topical edoxudine 3.0% cream in the treatment of recurrent genital herpes, Canadian Cooperative Study Group. J Infect Dis 164: 665-672, 1991.
28. [28] Ijichi K, Ashida N, Varia S, Machida H: Topical treatment with BV-araU of immunosuppressed and immuno-competent shaved mice cutaneously infected with herpes simplex virus type 1. Antiviral Res 21: 47-57, 1993.